ArticleFrontiers in microbiology2023
The associations between gut microbiota and chronic respiratory diseases: a Mendelian randomization study.
Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Risk factors for idiopathic pulmonary fibrosis: an umbrella review of meta-analyses and mendelian randomization analyses.BMC pulmonary medicine · 2026Pooled it
- Genetic liability of gut microbiota for idiopathic pulmonary fibrosis and lung function: a two-sample Mendelian randomization study.Frontiers in cellular and infection microbiology · 2024Pooled it
- The Gut-Lung Microbiome Axis in Alveolar Stem Cell Regeneration and Lung Repair.Microorganisms · 2026Review
- The clinical and translational perspectives on the lung microbiome in interstitial lung diseases: a bibliometric review.Journal of thoracic disease · 2026Article
- Liuweidihuang Pill Attenuates Early Bleomycin-Induced Pulmonary Fibrosis in Mice and Is Associated with Gut Microbiome.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Integrated analysis of gut microbiome and fecal metabolome reveals potential non-invasive biomarkers for early-stage silicosis.Microbiology spectrum · 2026Article
- Host mScientific reports · 2026Article
- The gut-lung axis in childhood asthma: from early-life programming to microbiome-informed precision medicine-a narrative review.Frontiers in immunology · 2026Review
- Research Advances on the Impact of Gut Microbiota on COPD: Exploring New Perspectives on the Microbiota-Gut-Lung Axis.Current microbiology · 2025Review
- Association of medium-chain acyl-CoA dehydrogenase with the risk of diabetic kidney disease: a mendelian randomized study.Hormones (Athens, Greece) · 2025Article
- B. adolescentis alleviates inflammation and suppresses PGE2 through remodling gut microbiota to attenuate pulmonary fibrosis in aging mice.NPJ science of food · 2025Article
- Genetic prediction of immune cells, inflammatory proteins, and metabolite-mediated association between gut microbiota and COPD: a Mendelian randomization study.Scientific reports · 2025Article
- Causality of genetically determined gut microbiota on lung cancer: a Mendelian randomization study.Journal of thoracic disease · 2025Article
- Causal Effects Between Genetically Determined Human Serum Metabolite Levels on the Risk of Idiopathic Pulmonary Fibrosis: A Mendelian Randomization Study.The clinical respiratory journal · 2025Article
- Article
- Review
- Gut-Heart Axis: Microbiome Involvement in Restrictive Cardiomyopathies.Biomedicines · 2025Review
- The Causal Relationship Between Gut and Skin Microbiota and Chronic Obstructive Pulmonary Disease:A Bidirectional Two-Sample Mendelian Randomization Analysis.International journal of chronic obstructive pulmonary disease · 2025Article
- The Impact of Gut Microbiota on Chronic Obstructive Pulmonary Disease: A Dual-Sample Mendelian Randomization Study.International journal of chronic obstructive pulmonary disease · 2025Article
- Overview of multi-omics approaches for pulmonary sarcoidosis.EC pulmonology and respiratory medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Growing evidence indicates that variations in the composition of the gut microbiota are linked to the onset and progression of chronic respiratory diseases (CRDs), albeit the causal relationship between the two remains unclear. Methods: We conducted a comprehensive two-sample Mendelian randomization (MR) analysis to investigate the relationship between gut microbiota and five main CRDs, including chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF), sarcoidosis, and pneumoconiosis. For MR analysis, the inverse variance weighted (IVW) method was utilized as the primary method. The MR-Egger, weighted median, and MR-PRESSO statistical methods were used as a supplement. To detect heterogeneity and pleiotropy, the Cochrane and Rucker Q test, MR-Egger intercept test, and MR-PRESSO global test were then implemented. The leave-one-out strategy was also applied to assess the consistency of the MR results. Results: Based on substantial genetic data obtained from genome-wide association studies (GWAS) comprising 3,504,473 European participants, our study offers evidence that several gut microbial taxa, including 14 probable microbial taxa (specifically, 5, 3, 2, 3 and 1 for COPD, asthma, IPF, sarcoidosis, and pneumoconiosis, respectively) and 33 possible microbial taxa (specifically, 6, 7, 8, 7 and 5 for COPD, asthma, IPF, sarcoidosis, and pneumoconiosis, respectively) play significant roles in the formation of CRDs. Discussion: This work implies causal relationships between the gut microbiota and CRDs, thereby shedding new light on the gut microbiota-mediated prevention of CRDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.